Amgen (AMGN) Revenue & Revenue Breakdown
Amgen Revenue Highlights
Latest Revenue (Y)
$28.19B
Latest Revenue (Q)
$8.39B
Main Segment (Y)
Other Products
Main Geography (Y)
UNITED STATES
Amgen Revenue by Period
Amgen Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $28.19B | 7.09% |
| 2022-12-31 | $26.32B | 1.32% |
| 2021-12-31 | $25.98B | 2.18% |
| 2020-12-31 | $25.42B | 8.83% |
| 2019-12-31 | $23.36B | -1.62% |
| 2018-12-31 | $23.75B | 3.93% |
| 2017-12-31 | $22.85B | -0.62% |
| 2016-12-31 | $22.99B | 6.14% |
| 2015-12-31 | $21.66B | 7.97% |
| 2014-12-31 | $20.06B | 7.43% |
| 2013-12-31 | $18.68B | 8.17% |
| 2012-12-31 | $17.27B | 10.80% |
| 2011-12-31 | $15.58B | 3.51% |
| 2010-12-31 | $15.05B | 2.81% |
| 2009-12-31 | $14.64B | -2.41% |
| 2008-12-31 | $15.00B | 1.57% |
| 2007-12-31 | $14.77B | 3.53% |
| 2006-12-31 | $14.27B | 14.79% |
| 2005-12-31 | $12.43B | 17.82% |
| 2004-12-31 | $10.55B | 26.26% |
| 2003-12-31 | $8.36B | 51.29% |
| 2002-12-31 | $5.52B | 37.54% |
| 2001-12-31 | $4.02B | 16.45% |
| 2000-12-31 | $3.45B | 7.62% |
| 1999-12-31 | $3.20B | 21.27% |
| 1998-12-31 | $2.64B | 12.64% |
| 1997-12-31 | $2.35B | 6.71% |
| 1996-12-31 | $2.20B | 15.46% |
| 1995-12-31 | $1.90B | 17.52% |
| 1994-12-31 | $1.62B | 19.57% |
| 1993-12-31 | $1.35B | - |
Amgen generated $28.19B in revenue during NA 2023, up 7.09% compared to the previous quarter, and up 118.71% compared to the same period a year ago.
Amgen Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $8.39B | 13.41% |
| 2024-03-31 | $7.40B | -9.76% |
| 2023-12-31 | $8.20B | 18.73% |
| 2023-09-30 | $6.90B | -1.19% |
| 2023-06-30 | $6.99B | 14.43% |
| 2023-03-31 | $6.11B | -10.73% |
| 2022-12-31 | $6.84B | 2.81% |
| 2022-09-30 | $6.65B | 0.88% |
| 2022-06-30 | $6.59B | 5.71% |
| 2022-03-31 | $6.24B | -8.88% |
| 2021-12-31 | $6.85B | 2.09% |
| 2021-09-30 | $6.71B | 2.76% |
| 2021-06-30 | $6.53B | 10.59% |
| 2021-03-31 | $5.90B | -11.05% |
| 2020-12-31 | $6.63B | 3.29% |
| 2020-09-30 | $6.42B | 3.50% |
| 2020-06-30 | $6.21B | 0.73% |
| 2020-03-31 | $6.16B | -0.58% |
| 2019-12-31 | $6.20B | 8.02% |
| 2019-09-30 | $5.74B | -2.28% |
| 2019-06-30 | $5.87B | 5.65% |
| 2019-03-31 | $5.56B | -10.80% |
| 2018-12-31 | $6.23B | 5.52% |
| 2018-09-30 | $5.90B | -2.56% |
| 2018-06-30 | $6.06B | 9.09% |
| 2018-03-31 | $5.55B | -4.27% |
| 2017-12-31 | $5.80B | 0.50% |
| 2017-09-30 | $5.77B | -0.64% |
| 2017-06-30 | $5.81B | 6.33% |
| 2017-03-31 | $5.46B | -8.40% |
| 2016-12-31 | $5.96B | 2.65% |
| 2016-09-30 | $5.81B | 2.16% |
| 2016-06-30 | $5.69B | 2.91% |
| 2016-03-31 | $5.53B | -0.16% |
| 2015-12-31 | $5.54B | -3.27% |
| 2015-09-30 | $5.72B | 6.57% |
| 2015-06-30 | $5.37B | 6.70% |
| 2015-03-31 | $5.03B | -5.59% |
| 2014-12-31 | $5.33B | 5.96% |
| 2014-09-30 | $5.03B | -2.88% |
| 2014-06-30 | $5.18B | 14.58% |
| 2014-03-31 | $4.52B | -9.78% |
| 2013-12-31 | $5.01B | 5.54% |
| 2013-09-30 | $4.75B | 1.47% |
| 2013-06-30 | $4.68B | 10.41% |
| 2013-03-31 | $4.24B | -4.14% |
| 2012-12-31 | $4.42B | 2.36% |
| 2012-09-30 | $4.32B | -3.53% |
| 2012-06-30 | $4.48B | 10.60% |
| 2012-03-31 | $4.05B | 1.89% |
| 2011-12-31 | $3.97B | 0.74% |
| 2011-09-30 | $3.94B | -0.38% |
| 2011-06-30 | $3.96B | 6.83% |
| 2011-03-31 | $3.71B | -3.51% |
| 2010-12-31 | $3.84B | 0.66% |
| 2010-09-30 | $3.82B | 0.32% |
| 2010-06-30 | $3.80B | 5.90% |
| 2010-03-31 | $3.59B | -5.70% |
| 2009-12-31 | $3.81B | -0.08% |
| 2009-09-30 | $3.81B | 2.67% |
| 2009-06-30 | $3.71B | 12.24% |
| 2009-03-31 | $3.31B | -11.81% |
| 2008-12-31 | $3.75B | -3.20% |
| 2008-09-30 | $3.88B | 2.95% |
| 2008-06-30 | $3.76B | 4.18% |
| 2008-03-31 | $3.61B | - |
Amgen generated $8.39B in revenue during Q2 2024, up 13.41% compared to the previous quarter, and up 137.40% compared to the same period a year ago.
Amgen Revenue Breakdown
Amgen Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Otezla | $2.19B | $2.29B | - | - | - |
| Nplate | $1.48B | $1.31B | - | - | - |
| Kyprolis | $1.40B | $1.25B | - | - | - |
| Evenity | $1.16B | $787.00M | - | - | - |
| ENBREL | $3.70B | $4.12B | - | - | - |
| BLINCYTO | $861.00M | - | - | - | - |
| Aranesp | $1.36B | $1.42B | - | - | - |
| Prolia | $4.05B | $3.63B | - | - | - |
| Product and Service, Other | $1.28B | $1.52B | $1.68B | $1.18B | $1.16B |
| Repatha (evolocumab) | $1.64B | $1.30B | - | - | - |
| Vectibix | $984.00M | - | - | - | - |
| XGEVA | $2.11B | $2.01B | - | - | - |
| Other Products | $5.26B | $5.57B | - | - | - |
| Neulasta | - | $1.13B | - | - | - |
| Product | - | $17.30B | $15.19B | $13.78B | $11.79B |
Amgen's latest annual revenue breakdown by segment (product or service), as of Dec 23: Other Products (19.16%), Prolia (14.74%), ENBREL (13.46%), Otezla (7.97%), XGEVA (7.69%), Repatha (evolocumab) (5.95%), Nplate (5.38%), Kyprolis (5.11%), Aranesp (4.96%), Product and Service, Other (4.66%), Evenity (4.22%), Vectibix (3.58%), and BLINCYTO (3.13%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product and Service, Other | $329.00M | $363.00M | $355.00M | $303.00M | $259.00M | $287.00M | $415.00M | $313.00M | $507.00M | $575.00M | $386.00M | $412.00M | $309.00M | $319.00M | $298.00M | $267.00M | $316.00M | $274.00M | $297.00M | $271.00M |
| Aranesp | $349.00M | $319.00M | $323.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| BLINCYTO | $244.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| ENBREL | $567.00M | $1.01B | $1.03B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EVENITY | $342.00M | $307.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Kyprolis | $376.00M | $350.00M | $349.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Prolia | $999.00M | $1.11B | $986.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| TEPEZZA | $424.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| XGEVA | $561.00M | $527.00M | $519.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Repatha (evolocumab) | $517.00M | $417.00M | $406.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Nplate | $317.00M | $386.00M | $419.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| KRYSTEXXA | $235.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Vectibix | $247.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| TEZSPIRE | $173.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Otezla | $394.00M | $629.00M | $567.00M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Products | $1.37B | $200.00M | $1.64B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Product | - | - | $6.55B | $6.55B | $6.27B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Amgen's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Other Products (18.44%), Prolia (13.41%), ENBREL (7.61%), XGEVA (7.53%), Repatha (evolocumab) (6.94%), TEPEZZA (5.69%), Otezla (5.29%), Kyprolis (5.05%), Aranesp (4.69%), EVENITY (4.59%), Product and Service, Other (4.42%), Nplate (4.26%), Vectibix (3.32%), BLINCYTO (3.28%), KRYSTEXXA (3.16%), and TEZSPIRE (2.32%).
Amgen Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Non-US | $8.38B | $7.73B | $584.00M | $494.00M | $478.00M |
| UNITED STATES | $19.81B | $18.59B | $1.43B | $1.41B | $1.46B |
Amgen's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (70.26%), and Non-US (29.74%).
Quarterly Revenue by Country
| Country | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-US | $2.15B | $2.71B | $1.86B | $143.00M | $152.00M | $126.00M | $132.00M | $142.00M | $134.00M | $145.00M | $133.00M | $134.00M | $133.00M | $118.00M | $117.00M | $126.00M | $123.00M | $120.00M | $120.00M | $115.00M |
| UNITED STATES | $4.97B | $6.40B | $4.69B | $387.00M | $384.00M | $358.00M | $363.00M | $391.00M | $368.00M | $372.00M | $355.00M | $334.00M | $369.00M | $363.00M | $318.00M | $355.00M | $366.00M | $356.00M | $379.00M | $356.00M |
Amgen's latest quarterly revenue breakdown by geography, as of Mar 24: UNITED STATES (69.87%), and Non-US (30.13%).
Amgen Peer Comparison by Revenue
AMGN Revenue FAQ
What is Amgen’s yearly revenue?
Amgen's yearly revenue for 2023 was $28.19B, representing an increase of 7.09% compared to 2022. The company's yearly revenue for 2022 was $26.32B, representing an increase of 1.32% compared to 2021. AMGN's yearly revenue for 2021 was $25.98B, representing an increase of 2.18% compared to 2020.
What is Amgen’s quarterly revenue?
Amgen's quarterly revenue for Q2 2024 was $8.39B, a 13.41% increase from the previous quarter (Q1 2024), and a 20.07% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $7.4B, a -9.76% decrease from the previous quarter (Q4 2023), and a 21.15% increase year-over-year (Q1 2023). AMGN's quarterly revenue for Q4 2023 was $8.2B, a 18.73% increase from the previous quarter (Q3 2023), and a 19.84% increase year-over-year (Q4 2022).
What is Amgen’s revenue growth rate?
Amgen's revenue growth rate for the last 3 years (2021-2023) was 8.51%, and for the last 5 years (2019-2023) was 20.67%.
What are Amgen’s revenue streams?
Amgen's revenue streams in c 23 are Otezla, Nplate, Kyprolis, Evenity, ENBREL, BLINCYTO, Aranesp, Prolia, Product and Service, Other, Repatha (evolocumab), Vectibix, XGEVA, and Other Products. Otezla generated $2.19B in revenue, accounting 7.97% of the company's total revenue, down -4.37% year-over-year. Nplate generated $1.48B in revenue, accounting 5.38% of the company's total revenue, up 13.01% year-over-year. Kyprolis generated $1.4B in revenue, accounting 5.11% of the company's total revenue, up 12.51% year-over-year. Evenity generated $1.16B in revenue, accounting 4.22% of the company's total revenue, up 47.40% year-over-year. ENBREL generated $3.7B in revenue, accounting 13.46% of the company's total revenue, down -10.20% year-over-year. BLINCYTO generated $861M in revenue, accounting 3.13% of the company's total revenue Aranesp generated $1.36B in revenue, accounting 4.96% of the company's total revenue, down -4.15% year-over-year. Prolia generated $4.05B in revenue, accounting 14.74% of the company's total revenue, up 11.58% year-over-year. Product and Service, Other generated $1.28B in revenue, accounting 4.66% of the company's total revenue, down -15.90% year-over-year. Repatha (evolocumab) generated $1.64B in revenue, accounting 5.95% of the company's total revenue, up 26.16% year-over-year. Vectibix generated $984M in revenue, accounting 3.58% of the company's total revenue XGEVA generated $2.11B in revenue, accounting 7.69% of the company's total revenue, up 4.87% year-over-year. Other Products generated $5.26B in revenue, accounting 19.16% of the company's total revenue, down -5.51% year-over-year.
What is Amgen’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Amgen was Other Products. This segment made a revenue of $5.26B, representing 19.16% of the company's total revenue.